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a  b  s  t  r  a  c  t
Rift  Valley  fever  virus  (RVFV)  is a mosquito-borne  virus,  and  is the  causative  agent of Rift  Valley  fever
(RVF),  a zoonotic  disease  characterised  by an  increased  incidence  of  abortion  or foetal  malformation
in  ruminants.  Infection  in  humans  can  also  lead to clinical  manifestations  that  in severe  cases  cause
encephalitis  or  haemorrhagic  fever.  The  virus  is  endemic  throughout  much  of the  African  continent.
However,  the  emergence  of  RVFV  in the Middle  East,  northern  Egypt  and  the  Comoros  Archipelago  haseywords:
ift valley fever
irus
accine
highlighted  that  the  geographical  range  of  RVFV  may  be increasing,  and  has  led  to  the  concern  that  an
incursion  into  Europe  may  occur.  At present,  there  is a  limited  range  of  veterinary  vaccines  available
for  use  in  endemic  areas,  and  there  is  no licensed  human  vaccine.  In this  review,  the  methods  available
for  diagnosis  of RVFV  infection,  the  current  status  of vaccine  development  and  possible  implications  for
RVFV  emergence  in Europe,  are  discussed.
Crown Copyright  © 2015  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC  BY. Introduction
Rift Valley fever virus (RVFV) is a mosquito-borne virus of the
enus Phlebovirus, family Bunyaviridae [1]. The RVFV genome is
omposed of three segments of single-stranded RNA, referred to
s large (L), medium (M)  and small (S) [2]. The bunyavirus ribo-
ucleoproteins corresponding to each genomic segment appear
ircular when observed by electron microscopy [3], although a sim-
liﬁed schematic detailing the individual genome segments and
ene order is shown in Fig. 1. The L segment encodes the viral
NA-dependent RNA polymerase (L protein) [4]. The S segment
ncodes the nucleoprotein (N) and the non-structural NSs protein,
hich is a major determinant of virulence [5,6]. The M segment
ncodes at least four proteins: the structural glycoproteins Gn and
c, the non-structural protein Nsm, and a large 78-kDa glycopro-
ein (LGp) [7]. The structural glycoproteins mediate binding and
ntry via receptors on the target cell membrane. The function of
 This review is dedicated to Professor Richard M.  Elliott (1954-2015) for his
riendship, support and outstanding contributions to virology, especially in the ﬁeld
f  bunyavirus research.
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the 78-kDa glycoprotein is unclear, although it is thought to be
incorporated into virions matured in mosquito cells, where it may
facilitate transition between different host species, and function
during replication in the mosquito host [8]. However, due to its
ability to form a complex with the Gc glycoprotein [9], the 78-kDa
glycoprotein may  constitute a target for the immune system, and
could potentially contribute to novel vaccine development. Addi-
tionally, the virus does not encode a matrix protein so the surface
glycoproteins interact directly with the ribonucleoprotein [9].
RVFV is the causative agent of Rift Valley fever (RVF), a zoonotic
disease affecting both ruminants and humans. In ruminants, RVF is
characterised by neonatal mortality and an increased incidence of
abortion or foetal malformation [2,10,11]. Sheep are the species of
domestic animal most susceptible to RVFV infection, and new-born
lambs in particular [10,11]. Mortality rate is signiﬁcantly inﬂuenced
by the age of the animal; newborn lambs are highly susceptible,
with a mortality rate of greater than 90% in lambs less than a week
old, associated with acute necrotic hepatitis [9,12,13]. However,
the mortality rate in adult ruminants is generally lower, at 10–30%
[14]. The abortion rate can range between 40 and 100% [13] (Fig. 2).In comparison to the course of disease observed in animals,
pregnant woman and neonatal infants are not preferentially
affected [15]. Human infection with RVFV is generally asymp-
tomatic, and the majority of those with clinical symptoms present
icle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Schematic representation of the segmented RNA genome of RVFV, detailing
the  small (S), medium (M)  and large (L) segments in linear representation, adapted
from [47]. The black shaded areas of this schematic diagram, denoted at the 3′ and
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y′ end of each segment (not to scale), represent terminal sequences that are com-
lementary to each other, forming panhandle structures that give rise to a circular
ppearance when observed using electron microscopy [15].
ith a short febrile illness and no long term sequelae [16]. In some
ases, fever recurs with headaches for up to 10 days followed by
wo weeks of weakness before recovery [17]. However, a small
inority develop severe RVF disease, exhibiting early symptoms of
cute hepatitis with associated jaundice, renal failure and haemo-
rhagic complications [18,19]. Haemorrhagic manifestations may
nclude macular rash across the trunk of the body, ecchymosis on
imbs and eyelids, bleeding from the gums and gastrointestinal
ig. 2. Aborted sheep foetus. Picture courtesy of Professor Coetzer, University of
retoria, South Africa, made available through the Food and Agriculture Orga-
ization (FAO) Corporate Document Repository (http://www.fao.org/docrep/006/
4611e/y4611e05.htm) [accessed on 12th June 2015]. 33 (2015) 5520–5531 5521
mucosal membranes, low blood pressure, hematemesis, melaena
and hepatosplenomegaly [20,21]. If the patient survives the hepati-
tis, neurological manifestations may  include loss of vision and signs
of encephalitis [16]. The risk of fatality increases for patients with
jaundice, encephalitis or haemorrhagic disease, with a fatality rate
of 1–3%, which can be as high as 50% in patients with haemorrha-
gic complications [16]. Long-term sequelae are observed in a small
number of patients, where neurological disorders resulting from
encephalitis may  lead to blindness, hemiparesis, quadraparesis,
incontinence, hallucinations, locked-in syndrome or coma [22–24].
Animals become infected through a bite from an infected
mosquito, and there are a number of mosquito vectors that have
been shown to be naturally infected with RVFV, predominantly of
the Culex and Aedes genera (reviewed in [25]). The transmission
cycles of RVFV are summarised in Fig. 3. In addition, there can also
be animal-to-animal infection through direct contact with infected
tissues or ﬂuids [15], and animals may  also become infected
through the re-use of needles during vaccination; particularly in
regions with limited resources [26]. There may  also be the poten-
tial for lactating animals to infect their young via milk [27–29].
Human infection can also arise from a mosquito bite [30]. How-
ever, humans can become infected through exposure to infected
animals or animal tissues, since infected animals, and sheep in par-
ticular, can display high titre viraemia [31]. Following infection
with RVFV, both the innate and adaptive immune responses are
important for virus clearance [14,32]. Along with an innate immune
response, natural infection with RVFV in domestic ruminants leads
to the development of a neutralising antibody response, elicited by
the viral glycoproteins (Gn and Gc) and the nucleocapsid protein
[33–35].
RVF disease was ﬁrst reported in 1930, as a result of inves-
tigations into a high abortion rate amongst pregnant ewes
accompanied by a high mortality rate of newborn lambs, on a farm
in the Rift Valley region of Kenya, and the causative agent was  iden-
tiﬁed as a virus [10]. Many of the people who had come into contact
with infected animals and tissues developed illness characterized
by fever, headaches and malaise; one individual developed a sec-
ond fever accompanied by headaches, and retained defective vision
for a number of weeks afterwards. Subsequently, periodic out-
breaks occurred in Kenya and other east African countries including
Tanzania and Zambia [36,37], until RVFV was identiﬁed in South
Africa in 1951 [38]. The disease is now considered to be endemic
in sub-Saharan African countries, with periodic major outbreaks
occurring throughout much of the African continent, associated
with episodes of heavy rainfall and ﬂooding [39] (Fig. 4). Over
the past forty years, RVFV has been detected in African countries
outside its traditional enzootic region, including Egypt in 1977
[40], and west Africa, in Mauritania and Senegal in 1987 [41,42].
A further outbreak occurred in Mauritania in 2010 [43]. In 1990,
an outbreak of RVF was conﬁrmed outside of mainland Africa for
the ﬁrst time, on the Indian Ocean island of Madagascar [44]. In
2000, RVFV was  also detected in Saudi Arabia and Yemen [14,45],
and by 2007 its geographical range included the French island of
Mayotte in the Comoros Archipelago [46]. Likely explanations for
the detection of epizootics outside the usual RVFV enzootic regions
are the commercial movement of infected animals and possibly
windborne movement of infected mosquitoes [47]. The emergence
of RVF in the Middle East and Mayotte has highlighted that RVFV
may  be increasing its geographical range, giving rise to the concern
that it may  potentially reach the Mediterranean basin and Europe.
Outbreaks of RVFV cause a signiﬁcant disease burden, with large
numbers of livestock and humans affected. The outbreak in Saudi
Arabia in 2000 resulted in the death of an estimated 40,000 animals
from a range of species, with 8000–10,000 abortions in ruminants
[48]. Therefore, an incursion of this zoonotic virus into Europe could
potentially have a devastating impact on the livestock industry in
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Fig. 3. Schematic detailing the transmission cycles of RVFV; vectorial transmission (solid green arrows), direct transmission (solid red arrow) and vertical transmission
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tdashed red arrows). Red asterixes indicate where vaccine intervention would be
irology/units-groups/arboviruses-and-insect-vectors/research) [accessed on 12th 
s  referred to the web version of this article.)
ultiple countries, along with a signiﬁcant impact on animal and
uman health. The current status of diagnosis and vaccine develop-
ent for RVFV infection are reviewed, and the factors which may
xacerbate the potential emergence of RVFV in Europe are assessed.. Diagnosis of Rift Valley fever in animals and humans
Early detection of suspected cases is pivotal to ensure
imely control measures are implemented to reduce the diseasepriate. Adapted from an image available at (https://www.pasteur.fr/en/research/
015]. (For interpretation of the references to color in this ﬁgure legend, the reader
burden. The sudden onset of large numbers of abortions (‘abortion
storms’) and mortalities among young animals in affected livestock,
together with the appearance of the disease in humans, is consid-
ered characteristic of an RVF epidemic [49]. In humans, the clinical
recognition of acute haemorrhagic fever cases generally triggers
an outbreak investigation in endemic regions. However, clinical
diagnosis alone cannot be considered reliable as some animals,
for example camels, may have inapparent infections. Moreover,
infection of susceptible, adult non-pregnant ruminants is often
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Fig. 4. Map  detailing the distribution of RFV—data as of 2014, adapted from a map courtesy of Centers for Disease Control [CDC], Atlanta, USA (http://www.cdc.gov/vhf/rvf/
distribution-map.html) [accessed on 12th June 2015]. Countries with endemic RVF and signiﬁcant outbreaks are shown in red, countries with periodic cases of RVF and/or
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eferences to color in this ﬁgure legend, the reader is referred to the web  version of
ubclinical and hence outbreaks outside of the lambing or calving
easons can be easily missed. The clinical signs of RVF in animals
end to be nonspeciﬁc and differential diagnoses includes bru-
ellosis, Bluetongue, Wesselsbron disease, enterotoxemia, Bovine
phemeral fever, vibriosis, trichomonosis, Nairobi sheep disease,
eartwater, ovine enzootic abortion, toxic plant ingestion, bacterial
epticaemias, peste des petits ruminants, anthrax and Schmallen-
erg disease [50].
Reference laboratories are often responsible for the coordi-
ation of ﬁeld sampling and testing but with heterogeneous
aboratory coverage in some endemic regions, delays in diagnosingses of RVF or evidence of infection are shown in green. (For interpretation of the
rticle.)
the disease commonly occur. Laboratory diagnosis would ideally
rely upon a combination of serological and molecular approaches.
The usefulness of the chosen assay is dictated by the disease
kinetics i.e. the window in which particular virological markers
(e.g. virus, viral RNA, IgG, IgM, hepatic lesions) are likely to be
detected. There is likely to be some variability in disease kinetics
between humans and animal species due to variation in suscep-
tibility between species, and even within species [2,51,52]. RVFV
can be detected by classic virological methods which include virus
isolation [53], histopathology [54], antigen detection [55,56], anti-
body detection [57–59] and nucleic acid based assays [60–62]. For
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eporting RVFV in animals, the Ofﬁce International des Epizooties
OIE); World Organisation for Animal Health, require laboratory
onﬁrmation by at least two positive results from a combination of
ifferent diagnostic approaches preferably for the same specimen
.e. either positive for virus/viral RNA and antibodies or positive
or IgM and IgG with demonstration of rising titres between paired
erum samples collected 2–4 weeks apart [50].
.1. Histopathology
The collection of diagnostic tissues (e.g. liver) in formaldehyde
n the ﬁeld may  be beneﬁcial in remote areas where cold chains do
ot exist. The histopathological examination of the liver of affected
nimals (and humans) will reveal hepatic lesions characteristic of
VFV and immunostaining may  allow the speciﬁc identiﬁcation of
VF viral antigen in tissue [50,54].
.2. Virus isolation
RVFV can be isolated from whole blood or serum collected dur-
ng the acute (febrile) stage of the disease [53]. Post-mortem, the
irus can also be isolated from the brain, liver, spleen and organs
f the aborted foetus. In vivo isolation of RVFV can be performed
n suckling mice; however, the OIE recommends that this approach
hould be avoided in favour of in vitro virus isolation, due to animal
elfare and biosafety issues [50]. There are various cell cultures
hat can be successfully employed for in vitro isolation of RVFV
ncluding African green monkey kidney cells (Vero), baby hamster
idney (BHK) cells and AP61 mosquito cells. Mammalian cell lines
re generally preferred for RVFV isolation due to the consistent
ytopathic effect (rounding of the cells), with destruction of the
ell monolayer within 12–24 h post infection. Immunostaining or
everse-transcription polymerase chain reaction (RT-PCR) can be
sed to conﬁrm virus isolation.
.3. Serology
Serological diagnosis, usually by virus neutralisation assay
VNA) or enzyme-linked immunosorbent assay (ELISA), is com-
only used to conﬁrm RVFV infection in an affected individual
animal or human), during outbreak management and also to
etermine the prevalence of exposure to RVFV in a susceptible pop-
lation (surveillance). Several assays are available for the detection
f anti-RVFV antibodies in a variety of animal species. Both the
NA and ELISAs are highly speciﬁc, although there is the poten-
ial that they could be hindered by cross-reactivity between RVFV
nd other phleboviruses [15]. Alternative techniques such as the
ndirect Immunoﬂuorescence, agar gel immunodiffusion (AGID),
adioimmunoassays and complement ﬁxation are no longer used
50]. The haemagglutination inhibition assay (HIA), once widely
pplied for serological investigations of suspected animals, is now
arely used due to biosafety and logistical issues.
The Virus Neutralisation Assay is the gold standard serologi-
al assay, generally used for vaccine potency determination and
s the OIE prescribed test for international trade [50]. The test is
ighly speciﬁc and, unlike some ELISA based assays, can be applied
o serum from a wide range of host species. However, virus neu-
ralisation assays can only be performed in appropriate biosecurity
acilities as they involve the manipulation of live virus. Alterna-
ive RVFV neutralisation assays are being developed and validated,
hich eventually may  lead to assays which do not involve the hand-
ing of highly virulent RVFV in containment [63].
ELISAs can be employed to conﬁrm the presence of either
peciﬁc IgM antibodies, which appear transiently from 4 days
fter infection or speciﬁc IgG antibodies, which appear from 8
ays after infection and may  persist for several years [64,65]. The 33 (2015) 5520–5531
appearance of antibodies, usually following four to seven days
of clinical symptoms/signs, generally coincides with the gradual
disappearance of the virus in the blood. Hence, either serum or
blood samples collected for serological analysis may  contain live
virus and must therefore be inactivated prior to testing outside
of biocontainment. ELISAs are developed and widely applied
by OIE Reference Laboratories [50,65], and several have been
developed using either whole cell lysate derived from infected
cells or puriﬁed nucleocapsid protein as antigen [65–69]. However,
the commercially available ELISAs (IgG and IgM) are based upon
recombinant RVFV nucleocapsid protein, despite the potential
for high background issues with this antigen [70]. The detection
of IgM would suggest a current or recent infection. However,
IgG-based ELISAs cannot distinguish between past and current
infection unless paired serum samples are analysed (acute and
convalescent) and a four-fold increase in antibody titre observed.
An indirect ELISA based on the recombinant nucleocapsid pro-
tein of RVFV has been developed for the detection of speciﬁc
antibodies in human and animal sera [67]. This dual target assay
is designed to differentiate between infected and vaccinated ani-
mals (DIVA), an important factor when considering the ﬁnancial
burden of movement restrictions on suspect livestock and the reg-
ulatory requirements for vaccine licensing. In naturally occurring
infections, an antibody response against both N and NSs would be
expected whereas in individuals vaccinated with the attenuated
vaccines (NSs) only an antibody response to the N protein would
be observed [67].
A selection of European laboratories recently participated in a
ring trial, to directly compare their own  ELISAs with those from
other laboratories, along with a number of commercially available
ELISAs [59]. It was  concluded that, whilst further evaluations are
warranted particularly for IgM ELISAs, their ring trial supports the
use of commercially available ELISAs for both primary screening
and serological diagnosis.
2.4. Molecular methods
A more economical and rapid alternative to virus isolation is
the detection of viral RNA during the acute (febrile) phase of
the disease, when high levels of viraemia occur in both humans
and animals. After an initial incubation period of 2–6 days in
humans, the febrile phase occurs, and typically lasts 3–4 days
[2,71,72]. Thus, rapid responses are necessary to allow case con-
ﬁnement (to avoid nosocomial infections in humans) and provide
appropriate management and control decisions. A range of highly
sensitive nucleic acid based molecular tests have been developed
for RVFV including nested RT-PCR methods [61], quantitative real-
time PCR [60,73–78], multiplex PCR-based macroarray assay [79],
RT Loop-mediated isothermal ampliﬁcation (RT-LAMP) [62] and
recombinase polymerase ampliﬁcation (RPA) [80].
The RVF RT-LAMP ampliﬁes speciﬁc nucleic acid sequences
using a set of six primers by strand displacement activity of a
DNA polymerase [62,81]. Ampliﬁcation leads to the formation of
a DNA precipitate which is detectable by the naked eye. There
is no requirement for complex equipment and the assays can be
cheaply and easily applied in ﬁeld situations. The RVF RPA method
[80], an alternative isothermal ampliﬁcation method utilising three
oligonucleotides and a speciﬁc ﬂuorescent probe, has been shown
to be as sensitive as LAMP and quantitative real time RT-PCR (qRT-
PCR), but with the greater potential to be applied to a hand held
battery operated device for point of care or ﬁeld application.
The OIE recommends that viral RNA detection is undertaken
using locally validated methods [50], such as conventional gel based
RT-PCR or real-time RT-PCR. In a recent external quality assess-
ment (EQA), thirty expert laboratories from 16 countries tested a
blind panel of RVFV positive and negative samples using their local
accine
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olecular based RVFV test procedures. Twenty-eight of the thirty
aboratories (93%) reported the use of a qRT-PCR for which con-
istently high sensitivity and speciﬁcity was observed between the
aboratories, although less consistency was observed for the nested
T-PCR assays. Escadafal et al. [82] also highlighted the limita-
ions of employing highly speciﬁc probe based or nested molecular
ssays, which may  fail to detect the wide range of potentially cir-
ulating RVFV strains. The two more recently developed molecular
ssays (RT-LAMP and RPA) were also represented in the ring trial,
lbeit by single laboratories, and compared well to the qRT-PCR.
Whilst molecular techniques have proven useful during RVF
utbreaks [49], the short duration of viraemia (3–4 days [2,71,72]),
nd the dependence on specialised equipment and skills, still pose
hallenges to their widespread applicability for monitoring the
pread of the virus in the ﬁeld. However, molecular approaches
llow for the rapid identiﬁcation of the genetic lineages and hence
he source and pathogenicity of the viral strains involved in a RVF
utbreak [83]. In addition, the RVF viral load is predictive of dis-
ase outcome, thus the use of quantitative real time assays may
nable clinicians to target individuals with high viral loads (poor
rognosis) for special intensive clinical management [84]. Sensi-
ive and speciﬁc molecular assays may  also be used for the early
etection of RVFV RNA in mosquito pools thereby contributing to
isease surveillance, vector species identiﬁcation and disease con-
rol [45,77,85].
. Vaccination and vaccine development
Vaccination to protect against RVFV remains problematic.
hilst there are no licensed vaccine preparations for use in
umans, three licensed veterinary vaccines are being utilised to
rotect ruminant populations, which are summarised in Table 1.
espite the availability of the licensed live attenuated (Smith-
urn vaccine) and inactivated vaccine preparations, both have
imitations to their use in endemic regions. Additionally, the live
ttenuated MP-12 vaccine has conditional licensure in the US,
nd the Clone-13 vaccine has also been licensed in South Africa
nd Zimbabwe [50]. However, the potential for co-infection and
eassortment between vaccine and wildtype viruses, suggests that
here is still an urgent requirement for a new generation of vet-
rinary RVFV vaccines, and a safe and efﬁcacious human vaccine.
 successful vaccine would predominantly be applied throughout
frica, mainly in resource-limited settings, therefore a consider-
tion of the cost to the farmer would be a particularly important
art of the development process.
.1. Inactivated vaccines
As for many viral pathogens, the development of vaccines for
VFV started with the use of inactivated material. The ﬁrst reported
reparation, the Entebbe vaccine, was based on a formalin inactiv-
ted mosquito derived virus that had undergone repeated passage
n mice. The ﬁrst inactivated vaccine was named NDBR103 and
able 1
ist of veterinary RVFV vaccines available [50,100]. n/a = not applicable.
Smithburn live attenuated
virus vaccine
Inactivated virus vaccines 
Virus origin Mosquito, Uganda, 1948 Field strains (South Africa
and Egypt)
Attenuation >200 passages in mouse
brain
n/a 
Production medium BHK cells BHK cells 
Regimen Single dose Requires booster and
annual revaccination.
Licensed Yes Yes  33 (2015) 5520–5531 5525
represented the 184th passage of the Entebbe strain followed by
ampliﬁcation in African Green Monkey cells to produce a large
stock from mouse sera [86]. This vaccine was  utilised for vacci-
nation of a group of 963 UN soldiers on a three-dose regime. Of
those that received all three doses (administration of 1 ml  subcuta-
neously on days 0, 7–10 and 28–30) the majority seroconverted
with the highest antibody titres being reached six weeks post-
vaccination [87]. A further development of this formalin-ﬁxed
vaccine was made with the production of TSI-GSD 200, a variation
on the original preparation that was  also trialled with the vacci-
nation of service troops. Data from a 12-year trial supports the
longevity of protective response for this latter preparation suggest-
ing that TSI-GSD-200 provides long-term immunity in vaccinated
humans following a primary inoculation and single boost schedule
[88]. Whilst such inactivated preparations can elicit a neutralising
response, the requirement for booster vaccinations makes utility
within a predominantly resource-limited agricultural setting prob-
lematic [89]. As such, live attenuated vaccines were developed, for
use in animals and humans.
3.2. Live attenuated vaccines
The Smithburn live attenuated RVFV vaccine was ﬁrst devel-
oped in Uganda for use in animals in the 1950s following repeated
passage of a mosquito-derived virus in mouse brain. The vaccine
is signiﬁcantly attenuated and has been used proactively in Kenya
and South Africa. Despite the successes seen with the Smith-
burn vaccine, problems regarding residual pathogenicity have
been reported, and furthermore the potential for teratogenic and
abortofacient effects following administration have been observed.
This was  demonstrated by Botros et al. [90] who reported that
administration of the vaccine to European breeds of cow (n = 100)
led to abortion in 29% of pregnant animals. A group of twenty preg-
nant buffaloes were also vaccinated in this study with no abortions
being reported. Sample size prevented statistical assessment of
the study although molecular tests demonstrated that abortion
was most likely caused by foetal infection following vertical
transmission of vaccine virus [90]. Therefore, whilst this vaccine
has found some utility in agricultural practices, the potential
for reversion to virulence has meant that the vaccine is con-
traindicated in areas where RVFV has not been detected. Further
studies are required to establish the determinants of virulence for
this vaccine. Additionally, molecular analysis has suggested that
reassortment among RVFV isolates may  occur in nature, which has
implications for vaccination with live attenuated vaccines during
an outbreak [91]. The use of such vaccines during an outbreak
may  lead to the vaccination of a viraemic animal, providing an
opportunity for reassortment between wild and vaccine viruses,
which has the potential to increase the diversity of circulating
RVFV strains [47]. Reassortants containing one attenuated and
two virulent segments have been shown to be attenuated [92],
therefore a reassortment event between a wild and vaccine strain
could produce an attenuated virus which may  protect against RVF,
Clone-13 live attenuated virus
vaccine
MP-12 live attenuated virus
vaccine
Human, 1974 Human strain ZH548 (Egypt, 1977)
Natural deletion in NSs gene Multiple mutations in S, M and L
segments
Vero cells MRC-5 cells
Single dose Single dose
Yes—South Africa and Zimbabwe Conditionally licensed in US
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s long as attenuation markers were present in each segment of
he live attenuated vaccine strain [91].
.3. Alternative vaccines
Alongside the licensed vaccines a number of alternative vaccines
ave been developed that may, in the future, serve as appropriate
reparations for effective vaccination. Such alternatives result from
hemical treatment of existing preparations, further passage in a
ariety of species or development of recombinant vaccines using
everse genetics techniques.
.3.1. Clone 13
The Clone 13 vaccine is based on a naturally attenuated strain,
hich contains a large deletion in the main virulence factor, the NSs
ene [93]. Clone 13 is a plaque-derived clone of a Central African
train of RVFV isolated from a human, which was shown to be highly
mmunogenic, yet avirulent in mice and hamsters [93]. Experi-
ental vaccine trials in mice and ruminants have suggested that
his vaccine is safe, with no apparent side effects [5,94,95], and as
uch offers a further alternative to the Smithburn vaccine. However,
ntranasal inoculation with an NSs-deleted virus has been shown
o cause severe neurological disease in mice [96], implying that
Ss-deleted viruses may  still retain some virulence.
.3.2. MP-12
A  live attenuated vaccine for both human and animal use was
enerated following passage of human strains in the presence of
hemical mutagens [97]. The passage of isolates in the presence of
-ﬂuorouracil led to the establishment of a live attenuated virus
hat is temperature sensitive, and has been found to contain muta-
ions in all three of its genome segments, a feature of importance
hen considering the potential for reversion to virulence. The
esulting virus, termed MP-12, has been used to determine regions
f the RVFV genome that are important for attenuation with the
onclusion that mutations to the M and L segments primarily con-
ribute to attenuation seen in a murine model [92,98,99], although
utations in the S segment also contribute to attenuation to a lesser
xtent [100]. The assessment of MP-12 in both animal and human
accination trials have been encouraging with minimal teratogenic
ffects seen in ruminants [101,102] and suitable immunogenicity in
on-human primates following a high dose intravenous or aerosol
hallenge [103] being reported. Interest in this preparation as a
uman vaccine is high and warrants further investigation.
.3.3. Recombinant vaccines
Aside from the use of either killed vaccines or live attenuated
accines, the use of viral products including antigen and heterol-
gous vectors to express antigen has been assessed for RVFV.
tandard viral vectors that have found utility in elimination of other
iral diseases through expression of heterologous genes have been
ssessed. Historically, one of the most successful vectors for gly-
oprotein expression are poxviruses [104], and these viruses have
een used as vectors for RVFV proteins previously [105,106]. Build-
ng on seminal studies, recombinant vaccinia viruses expressing Gn
nd Gc have been assessed in backbone strains of vaccinia that con-
ain immunostimulatory genes cloned in place of vaccinia virulence
enes. Preparations were shown to remain highly attenuated in
oth mice and non-human primates and were able to generate good
eutralising antibody titres although further studies in ruminants
re warranted [107]. Similarly, a replication-deﬁcient chimpanzee
denovirus vector encoding RVFV envelope glycoproteins Gn and
c induced a neutralising antibody and robust CD8+ T cell response
n mice [108]. Related to this, a further study reported the use
f another ruminant pathogen as a vehicle for RVFV glycoprotein
xpression to generate a bivalent DIVA vaccine for RVFV that had 33 (2015) 5520–5531
the additional advantage of protecting animals against Lumpy Skin
Disease virus (LSDV) [35,109]. This form of vaccine elicited protec-
tion against sheep pox and RVFV as well as neutralising antibodies
to both LSDV, RVFV and the closely related capripox virus follow-
ing vaccination. No adverse effects were seen following vaccination
and as such this formulation represents a promising bivalent DIVA
vaccine for LSDV and RVFV [35,110,111]. Other preparations involv-
ing modiﬁed vaccinia virus Ankara (MVA) expression of GnGc have
also been assessed in murine models and may  also represent future
alternatives for vaccine development [111]. Importantly, recombi-
nant pox virus based vaccine preparations offer DIVA potential that
is not seen with other vaccines, with the exception of Clone 13,
which also offers the potential for DIVA albeit through the absence
of the NSs gene [15,112]. Other preparations including subunit
vaccines [33,113,114] and DNA vaccines [115–117] have all been
developed but are often poorly immunogenic and require several
inoculations to elicit high titre neutralising antibodies (reviewed in
[118]).
Reverse genetics-based vaccines have been developed for RVFV,
and the ability to make cDNA copies of each segment of the RVFV
genome and rescue live virus in vitro has had signiﬁcant impli-
cations for the generation of novel vaccines across many virus
families [119–123]. Avirulent recombinant RVFVs have been devel-
oped and tested in both rodents [112] and ruminants [124–126],
and an MP-12 vaccine with an NSm deletion has been shown to
be immunogenic in calves [125]. This approach also has the beneﬁt
of potentially complying with DIVA, although there is currently no
data on NSm antibody prevalence in RVFV-positive sera to conﬁrm
the NSm as an effective antibody absence DIVA marker. As an addi-
tional alternative to the existing preparation, the MP-12 strain has
been generated from clones, and a recombinant virus produced,
where the genetic makeup has been altered from tri-segmented
to bi-segmented [127]. The advantage of this recombinant is the
removal of the potential for segment reassortment following co-
infection with wild-type virus that could have implications for
biosafety. A further adaptation to the MP-12 strain has been made
through the deletion of the NSs gene, thus combining the advan-
tages of the original MP-12 strain with elements of the Clone 13
vaccine that enable DIVA [128]. However, the NSs protein is known
to elicit a variable antibody response in naturally-infected rumi-
nants, which questions the application of NSs-speciﬁc antibodies
as criteria to differentiate natural infection from vaccination [129].
MP-12 has also been genetically-modiﬁed to encode a mutant
envelope protein, which created a mutant single-cycle replicable
vaccine which did not cause any clinical disease in mice [130].
A critical development using a thorough understanding of RVFV
molecular biology has been the ability to rescue recombinant virus-
like particles (VLPs) and intact viruses. VLPs generated from the
nucleoprotein [131] and glycoproteins [132] have been developed
as potential vaccines against RVF. A number of groups have suc-
cessfully recovered virulent and avirulent strains of the virus and
utilised this technology to investigate the function of RVFV proteins
[133–135]. This achievement has opened the way  for deﬁning the
mechanisms of avirulence and for intelligent design of a vaccine
against RVF. However, the main disadvantages for this approach
are based upon resistance to the use of genetically recombinant
products, particularly in humans, and animals entering the food-
chain. Further studies with such recombinant vaccines are certainly
warranted to assess applicability in the ﬁeld.
4. RVFV emergence implications for the lack of available
vaccine
Predicting the emergence and spread of RVFV has been the
subject of considerable research in recent years. One area of
accine
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articular development has been the application of spacial mod-
lling using environmental parameters to predict RVF outbreaks.
atellite images of sea surface temperatures, rainfall anomalies,
nd vegetation have been incorporated into models and have suc-
essfully predicted RVF outbreaks in sub-Saharan Africa [136,137].
his multi-disciplinary predictive surveillance for RVF has also been
xtended to aid in preparedness for a range of vector- and water-
orne diseases (including leishmaniasis, malaria, dengue fever,
apanese encephalitis, chikungunya fever, tick-borne infections,
bola virus disease and other haemorrhagic fevers, hantavirus
isease) throughout regions of the Americas, Africa and Asia
138]. Under a multidisciplinary programme, initiated by the US
lobal Emerging Infections Surveillance and Response System
DoD-GEIS), data sets and information derived from eco-climatic
emote sensing activities, ecologic niche modelling, arthropod vec-
or, animal disease host and human disease surveillance for febrile
llnesses, are collated into a predictive surveillance model. The
odel generates advice and alerts on emerging infectious disease
utbreaks (early warning system). In combination with improving
apid ﬁeld based diagnostics and sero-surveillance programmes,
uch model based approaches will support the early detection of
merging disease outbreaks and contribute to timely public health
esponses [139]. More recently, methods to link mathematical
odels for RVFV with broad-scale spatiotemporal data for realis-
ic landscapes have been developed to assess receptivity for RVF
140]. This data-driven model was applied to the Central Valley of
alifornia to assess the threat RVFV poses to North America, and
as the potential to assist in the prioritisation of when and where
o focus control strategies, including animal vaccination, during an
pidemic.
The expansion of RVF to the Middle East, in association with
 changing climate and an increase in livestock trade has high-
ighted RVFV as a threat to Europe. The importation of millions
f sheep and goats from RVFV-endemic regions of Africa to the
iddle East for ritual slaughter during festival periods is one poten-
ial route for the introduction of RVFV to Middle Eastern countries
nd potentially the Mediterranean basin [141,142]. It should be
oted however, that at present Egypt protects livestock from RVF
y vaccination, although there are some import cases along the
udan border. Saudi Arabia and Yemen only appear to have activ-
ty in a shared epidemic zone along the west coast. However, the
roximity of Mediterranean countries to areas with endemic RVF,
eriodic cases or serological evidence of RVF is highlighted in Fig. 4.
his is a concern which cannot be ignored, since high numbers of
VFV-competent mosquito vector species are present in Europe
143], and modelling studies have suggested that climate change
as the potential to increase the risk of incursion of other com-
etent mosquito species for RVFV into Europe [144]. However, a
ossible reason why RVFV has not yet spread into Europe may
e the seasonality of temperatures and vector populations, which
eads to conditions which are perpetually changing [140]. This may
imit the opportunity for RVFV to become established in European
osquito populations, since variation in climate, vector and host
ensity would inﬂuence vector competence, vectoral capacity and
ector lifespan, in comparison to the more stable temperatures
bserved in Africa [25]. This also implies that an incursion may  not
rogress to a large scale outbreak in Europe, although there remains
n increased risk of RVFV entering Europe via the Mediterranean
asin, through uncontrolled livestock movement associated with
rowing human populations and the increased demand for meat
25].
There are therefore a number of considerations which should act
s drivers to progress vaccine development, including the presence
f competent mosquito vectors in Europe. More than 65 mosquito
pecies are described as potential vectors of RVFV worldwide,
ith species in the genera Aedimorphus (Aedes), Culex, Anopheles, 33 (2015) 5520–5531 5527
Neomelaniconion and Ochlerotatus considered natural hosts and pri-
mary vectors [25,145–148]. Of the vectors identiﬁed as competent
for RVFV, a number are present in Europe, including Culex pipiens
s.l. Therefore, the emergence of the virus in Europe may  have the
potential to spread rapidly throughout resident mosquito popula-
tions, and lead to an epidemic. Furthermore, climate change may
lead to an increase in the already high numbers of RVFV-competent
mosquito vector species in Europe, and an increase in risk of incur-
sion of RVFV into Europe [25,143,144]. This has been investigated
through modelling studies in the Netherlands, which identiﬁed
some regions with a high transmission potential for RVFV, along
with a risk of persistence of infection [149]. This study showed that
the areas most at risk in the Netherlands had a low density of live-
stock, and therefore a high vector–host relationship, and that the
risk of persistence is due to the presence of Culex pipiens s.l. rather
than the less abundant Aedes vexans.  However, despite the wide
range of potential mosquito vectors for RVFV, the virus has yet to be
detected in other regions outside Africa and the Middle East, and the
reasons for this are unknown. Although primarily a mosquito-borne
viral disease [14,25,146,150,151], RVFV has also been isolated from
an array of other haematophagous arthropods including ticks and
sand ﬂies, but their signiﬁcance to transmission cycles has yet to be
established [15,152–156]. However, this does raise the possibility
that following introduction into Europe, RVFV could spread within
populations of alternative haematophagous arthropods.
Without the availability of efﬁcacious veterinary vaccines, the
emergence of RVFV in Europe could have a potentially devastat-
ing impact on the agriculture industry, from both an animal health
and an economic aspect. The cross-border livestock trade through-
out Eastern Africa is one of the most signiﬁcant areas of economic
growth, and is estimated to exceed US$60 million per year [157].
As a result of the 2007 outbreak in Tanzania, 52.4% of regions in the
country were affected, resulting in an estimated loss due to live-
stock mortality of over $4 million for cattle and $2 million for sheep
and goats, along with a signiﬁcant decline in international animal
trade [158]. Furthermore, outbreaks in domestic animal popula-
tions may  also lead to transmission to humans through contact
with infected livestock. The 2007 outbreak in Sudan resulted in 698
human cases, of which 222 were fatal (case fatality rate of 31.8%)
[159]. Infection through direct contact with blood from infected
animals has been reported in humans [160] and laboratory acquired
infections have been documented [17,161]. With no human vac-
cine available, or effective antivirals, human death could result. This
potential for infection by direct contact or aerosol, combined with
severe clinical manifestations, has highlighted the possible utility
of RVFV as a bio-weapon, and has generated renewed interest in
animal models and vaccines [162].
5. Concluding remarks
A robust cohort of methods are readily available for the diagno-
sis of RVFV infection, therefore new cases are likely to be diagnosed
efﬁciently in the event of an epidemic in Europe. However, the lack
of an approved vaccine against RVFV for use in humans, along with
limitations to veterinary vaccines, is a major concern. A change
in climate to warmer and wetter conditions has the potential to
increase the risk of incursion of additional competent mosquitoes
for RVFV into Europe, and propagate existing mosquito popu-
lations. Additionally, in some Aedes species, infected diapaused
eggs have been shown to survive during inter-epizootic, dry or
cold periods, leading to the possibility of over-wintering [163]. If
introduced into Europe, RVFV therefore has the potential to spread
among local mosquito populations, with the potential to cause
epidemics with signiﬁcant impacts on human and animal health.
Due to the threat of emergence outside Africa, veterinary vaccines
5 accine
s
f
a
t
a
t
c
f
a
c
c
F
m
c
c
r
b
t
R
o
s
c
a
t
A
r
L
a
t
w
F
R528 K.L. Mansﬁeld et al. / V
hould be stockpiled in non-endemic areas [160]. The potential for
uture RVFV epidemics also drives an urgent requirement for an
pproved human vaccine. If the virus were to emerge outside the
raditional endemic areas, the lack of an approved human vaccine,
long with the potential for infection via direct contact or aerosol,
he severity of clinical disease and the ease of access to samples,
ould threaten both humans and domestic animals. There is there-
ore an urgent requirement for a safe and efﬁcacious human vaccine
gainst RVFV infection, in addition to more reliable veterinary vac-
ines. Along with the need for improved vaccines, there are other
onsiderations to help prevent an incursion of RVF into Europe.
irst, the spread of RVF throughout Africa needs to limited, and this
ay  be achieved through the stockpiling of vaccines, improved vac-
ination campaigns, and the provision of international funding to
ompensate affected farmers, who may  otherwise be reluctant to
eport outbreaks within their herds. The OIE has created vaccine
anks for a number of diseases, which is an important advance
owards counteracting the global spread of animal diseases, and a
VFV vaccine bank is planned. In addition, a greater understanding
f transmission pathways within Africa may  help to prevent the
pread of RVFV from Africa to Europe and other continents. This
ombined strategy would provide a truly One Health One World
pproach to what is considered one of the most serious arbovirus
hreats to human and animal health [164].
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